Regulation 3 New regulation 18 of the Pharmaceutical Regulations
After regulation 17 of the Pharmaceutical Regulations (transitional provisions), insert—
“Transitional provisions in respect of drugs or appliances supplied in accordance with SSPs
18.(1)This paragraph applies where—
(a)pursuant to paragraph 5A(4)(a) or 15A(2)(a) of Schedule 2, a pharmacist, or a dispensing doctor is required to endorse a prescription or an associated batch issue; and
(b)the Board (or RBSO acting on the Board’s behalf) is only able, or is also able, to process a claim for pharmaceutical reimbursement in respect of the product being provided if the claim is made using a separate token (“a dispensing token”), which is in a form approved by the Department for the purposes of making such claims.
(2)Where paragraph (1) applies—
(a)to the extent required or permitted by the Drug Tariff, a dispensing token recording the provision of the product is treated as being, as regards that product, the prescription for product reimbursement purposes;
(b)if the manner for recording the provision of the product in the dispensing token is provided for in the Drug Tariff, the recording of the provision of the product in the dispensing token must be in the manner provided for in the Drug Tariff; and
(c)the manner of the endorsement of the original prescription or associated batch issue (where provided for in the Drug Tariff) may vary, depending on whether or not it is to be used for product reimbursement purposes.
(3)Where, by virtue of paragraph (2)(a), a dispensing token is the prescription for product reimbursement purposes, paragraph 5A(6) of Schedule 2 applies as if the reference to paragraph 5A(4)(a) of that Schedule included a reference, in the alternative, to paragraph (2)(a).
(4)For the purposes of this regulation, “pharmaceutical reimbursement” means pharmaceutical remuneration of the type payable to those providing pharmaceutical services in accordance with Part 2 or Part 3 of Schedule 2 to these Regulations.”.